Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

BRCA1 deletion

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

BRCA1 deletion	Prostate Cancer	BRCA1 deletion	Prostate Cancer	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3
BRCA1 deletion	Ovarian Cancer	BRCA1 deletion	Ovarian Cancer	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3
BRCA1 deletion	Ovarian Cancer	BRCA1 deletion	Ovarian Cancer	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
BRCA1 deletion	Ovarian Serous Adenocarcinoma	BRCA1 deletion	Ovarian Serous Adenocarcinoma	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
BRCA1 deletion	Triple Negative Breast Cancer	BRCA1 deletion	Triple Negative Breast Cancer	PARP inhibitor Sensitive: D – Preclinical PARP inhibitor Sensitive : D	PARP inhibitor Sensitive: D – Preclinical PARP inhibitor Sensitive : D
BRCA1 deletion	Triple Negative Breast Cancer	BRCA1 deletion	Triple Negative Breast Cancer	olaparib Sensitive: D – Preclinical olaparib Sensitive : D	olaparib Sensitive: D – Preclinical olaparib Sensitive : D
BRCA1 deletion	Solid Tumor	BRCA1 deletion	Solid Tumor	PLX038 Sensitive: D – Preclinical PLX038 Sensitive : D	PLX038 Sensitive: D – Preclinical PLX038 Sensitive : D